Hepatocellular carcinoma as the Rose of Jericho:from the desert of sorafenib,to the blossoming of immunotherapy

作     者：Antonio D’Alessio Lorenza Rimassa 

作者机构：Department of Surgery&CancerImperial College LondonHammersmith HospitalLondonUK Department of Biomedical SciencesHumanitas UniversityPieve EmanueleMilanItaly Medical Oncology and Hematology UnitHumanitas Cancer CenterIRCCS Humanitas Research HospitalRozzanoMilanItaly 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第3期

页      面：485-488页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：sorafenib immunotherapy monoclonal 

摘      要：According to its etymology,the English word“liveris related to the verb“to live,and indeed there are few domains of oncology research as lively as liver *** therapeutic landscape of hepatocellular carcinoma(HCC)has been rapidly changing over the last years,after the successful introduction of immune checkpoint inhibitors(ICIs)as standard of care for the treatment of unresectable or metastatic HCC(uHCC).Following more than a decade of tyrosine kinase inhibitors(TKIs)as the only available treatment for advanced HCC,in 2020 the results of the IMbrave150 trial radically changed the therapeutic algorithm(1,2).The combination of the anti-programmed death ligand 1(PD-L1)monoclonal antibody(mAb)atezolizumab and the anti-vascular endothelial growth factor(VEGF)mAb bevacizumab outperformed sorafenib in terms of overall survival(OS)and progression-free survival(PFS),meeting both its co-primary *** combination has been recognised as the new first-line standard of care by all major scientific societies,and it has been approved by regulatory agencies worldwide(3).